Rapport Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Small Molecule Medicines for CNS & Neurological Disorders
Rapport Therapeutics is a public clinical-stage biotech (Nasdaq: RAPP) developing precision small molecules targeting TARP-containing AMPARs for epilepsy and other CNS disorders; completed $174M IPO in June 2024;
About
Rapport Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts. The company is developing a new class of precision small molecule medicines for neurological and psychiatric disorders by targeting Receptor-Associated Proteins (RAPs) — a family of proteins that modulate the function of ion channels in the brain. Rapport''s lead program, RAP-219, is an investigational small molecule that selectively inhibits TARP-gamma-8-containing AMPA receptors (AMPARs) — a receptor subtype concentrated in the hippocampus and limbic system — for the treatment of focal onset seizures (focal epilepsy) and other CNS conditions driven by hyperexcitability in these circuits.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.